2-methoxyestradiol (2-MeOE 2 ) treatment caused signi®-cant growth inhibition of H460 and A549 human lung cancer cell lines which contain wild-type p53. However, 2-MeOE 2 had a little eect on the p53 negative H358 and p53 mutated H322 cell lines. Western blot analysis indicated that 2-MeOE 2 treatment resulted in an eightfold increase in the endogenous wild-type p53 protein, while the level of the mutant p53 protein remained unchanged. TdT staining indicated that following 2-MeOE 2 -mediated increases in wildtype p53 protein, cells bypass the G 1 -S checkpoint of the cell cycle with 30 to 40% undergoing apoptosis. Introduction of anti-sense wt-p53 into wt-p53 cells abrogated the 2-MeOE 2 eect. A signi®cant portion of lung cancer retains the wild-type p53 gene therefore, 2-MeOE 2 may have therapeutic application.
Keywords: p53; lung cancer; apoptosis; methoxyestradiol; gene expression 2-methoxyestradiol (2-MeOE 2 ) is a natural metabolic biproduct of the human body formed by the hydroxylation of estradiol followed by O-methylation in the liver. Earlier studies indicated that this compound has a cytotoxic eect on the estrogen dependent breast cancer cell line MCF-7 (Lottering et al., 1992) and causes inhibition of DNA synthesis and abnormal metaphases in Chinese Hamster V79 cells in culture (Aizu-Yokota et al., 1995) . It has been shown that this drug also binds to the colchicine binding site of tubulin ®laments resulting in either inhibition of tubulin polymerization or alterations in the stability of microtubules in the MCF7 breast cancer cell line (Cushman et al., 1995) . 2-MeOE 2 inhibits endothelial cell migration and angiogenesis in vitro (Fotsis et al., 1994) . However, the exact mechanism by which 2-MeOE 2 inhibits target cell proliferation is still largely unknown. In this report we provide evidence that 2-MeOE 2 , can selectively post-transcriptionally induce functionally active wild-type p53 protein in human lung cancer cell lines and induce apoptosis. Therefore, 2-MeOE 2 could be used for the induction of p53 mediated programmed cell death in cancer cells where the p53 gene is retained in native wild-type form.
We tested the eect of 2-MeOE 2 treatment on the growth characteristics of ®ve dierent human lung cancer cell lines diering in their p53 status: H358 (p53 deleted), H322 (p53 mutated), H460 (wild-type p53), A549 (wild-type p53) H226b (wild-type p53). Initial dose response studies indicated a 5 mM concentration of 2-MeOE 2 treatment induced wildtype p53 and WAF1 proteins to a maximum level without toxicity (data not shown). Therefore, we used 2-MeOE 2 and 16-epiestriol, (a metabolite of estrogen with no growth inhibitory activity) which served as a negative control. We treated the lung cancer cell lines with 5 mM of 2-MeOE 2 or 16-epiestriol, and the growth of the cells was monitored for 5 days ( Figure  1a ). 2-MeOE 2 had a signi®cant growth inhibitory eect on the A549 and H460 cell lines which contain the wild-type p53, whereas it had virtually no growth inhibitory eect on the mutated p53 H322 cell line or on the p53 deleted H358 cell line.
Western blot analysis of the p53 protein after 2-MeOE 2 treatment indicated that this drug induced the wild-type p53 protein to a much higher level in cell lines carrying wild-type p53 (Figure 1b) . The wild-type p53 protein is induced six-to eightfold during 48 h of 2-MeOE 2 treatment in these lung cancer cell lines. The wild-type p53 manifests its pleiotropic eect by activation of a number of target genes. WAF1, one of the p53 gene targets, encodes a p21 WAF1/CIP1 protein of 21 000 Dalton molecular weight, an inhibitor of cyclindependent kinase required for the G 1 -S transition (ElDeiry et al., 1993) . Increased p53 levels after 2-MeOE 2 treatment caused activation of the p21 gene ( Figure  1b) . When the blots were reprobed with WAF1 monoclonal antibody, the H460 and A549 cell lines showed three-to ®vefold increases in p21 protein expression. However, p53 and p21 Western blots of the p53 mutated (H322), deleted (H358) and normal human bronchial epithelial cells (NHBE) showed no increase of p53 protein after 2-MeOE 2 treatment ( Figure 1c ). 2-MeOE 2 had no eect on p21 expression in H322 cells. p21 protein expression remained unchanged after drug treatment in H358 p53 deleted cells. A marginal increase of p21 protein was noticed in NHBE cells with no change in the p53 protein after 2-MeOE 2 treatment. Increase in p21 protein in these cells could be independent of p53 since p21 has been shown to be regulated by alternative pathways.
In order to determine if 2-MeOE 2 induced wild-type p53 is predominantly controlled by a post-transcriptional phenomenon, total RNA from H460 control cells and H460 cells treated with 2-MeOE 2 for 48 h were analysed by Northern blots. The blots were probed with radio labeled p53 cDNA (Figure 1d) . Results showed no change in the p53 mRNA levels after drug treatment indicating that 2-MeOE 2 had no eect on the expression of the wild-type p53 mRNA. Western blot analysis of p53 protein after 2-MeOE 2 and 16 Epiestriol treatment was performed using anti-p53 monoclonal antibody (Biotechnology Inc., Santa Cruz, CA) as described previously (Mukhopadhyay et al., 1995) . H460 (lanes 1 ± 3) and A549 (lanes 5 ± 7) cell lines were treated with 5 mM of 2-MeOE 2 or Epiestriol for 48 h and cell lysates were analysed by Western blotting using PAb 1801 anti p53 monoclonal antibody. Increased p53 protein in H460 cells treated with 2-MeOE 2 for 48 h was correlated with increased p53-DNA binding activity. We tested the ability of the p53 protein isolated from untreated and 2-MeOE 2 treated H460 cells for its ability to bind to the wildtype speci®c p53CON DNA sequence (GGA-CATGCCC-GGGCATCTCC). H460 cells were treated with 2-MeOE 2 for 48 h and then total nuclear extracts were prepared. There was a threefold increase in the p53 DNA binding activity in the nuclear extract of 2-MeOE 2 treated H460 cells as compared to the untreated control cells. Supershift analysis using anti-p53 monoclonal antibody was done to con®rm the binding of p53 protein to the consensus DNA binding elements (Figure 2 ). These data demonstrate that the wild-type p53 protein induced after 2-MeOE 2 treatment is functionally active. In the prevailing view, induction of wildtype p53-p21 WAF1/CIP1 causes G 1 arrest and apoptosis. However, in these lung cancer cell lines, induction of both wild-type p53 and p21 WAF1/CIP1 protein had no eect on the cell cycle. Cell cycle analysis indicated no evidence of G 1 arrest in these lung cancer cell lines after 2-MeOE 2 or epistriol treatment ( Figure  3a) . The cells were labeled with PI and cell cycle was analysed by FACScan. A peak representing apoptotic cells appeared in H460 and A549 cell lines treated with 2-MeOE 2 . A signi®cant increase in cell death was observed during the growth assay after 48 h of 2-MeOE 2 treatment of H460 and A549 cell lines although only a few dead cells were noticed in the H322 or in H358 cell lines after crystal violet staining.
To con®rm that the cells were dying due to apoptosis, both¯oating and adherent populations of cells were P end-labeled p53 CON oligos 5'-TCG AC GGA CAT G CCC GGG CAT GT CCG-3 for 20 min at room temperature and was analysed essentially as described elsewhere (Funk et al., 1992) . The supershift assay was performed using 1 ng of anti-p53 monoclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). Two copies of the palindromic oligonucleotide were made double stranded by self annealing in 0.1 M NaCl, heated to 908C, and allowed to cool slowly. There was a threefold higher level of p53-DNA binding activity in the nuclear extracts of 2-MeOE2-treated H460 cells (lane 4) as compared to untreated control cell extract (lane 2). Supershift analysis was done to con®rm that p53 protein was indeed binding to the consensus DNA binding element. Lane 3, showing protein supershift with control untreated H460 nuclear extract; lane 5, protein supershift with 2-MeOE 2 treated H460 cell nuclear extract. Lane 1, oligo only. Arrows indicated p53 speci®c band shift Figure 3 (a) Percentage distribution of cells in dierent cell cycle stages after 5 mM of Epiestriol (Me) or 2-MeOE 2 (Met) treatment for 48 h was studied by¯ow cytometry. H358 (p53 deleted), H322 (p53 mutated), and H460 (p53 wild-type) cell lines were treated and subjected to cell cycle analysis after propidium iodide (PI) staining (50 mg/ml) followed by 15 mg/ml RNase A treatment for 30 min at 378C and compared with untreated respective control cells (C). (b) Percentage of cells showing apoptosis was measured by FACScan after TdT staining. The apoptotic cells were labeled in situ with biotinelated dUTP in the reaction mixture employing exogenous terminal deoxynucleotidyl transferase (TdT) followed by¯uorescenated avidin binding. C, Control untreated cell line, Me, cells were treated with Epistriol; Met, cells were treated with 2-MeOE 2 Induction of p53 by methoxyestradiol T Mukhopadhyay and JA Roth pooled and ®xed in 70% methanol and stained with dUTP-labeled biotin followed by FITC-avidin for detection of DNA strand breaks associated with apoptosis by FACScan. The results indicated that 2-MeOE 2 treated H460 and A549 cells had undergone apoptosis (Figure 3b ). Cells were also stained with biotinylated dUTP for TUNEL assay to monitor the DNA fragmentation as shown in Figure 4 . H460 cells were grown in chamber slides and treated with the drugs and TdT staining was performed as described previously (Fujiwara et al., 1994) . Cells treated with epistriol or control mock treated cells showed little DNA fragmentation while 2-MeOE 2 treated cells displayed many apoptotic bodies. However, the normal bronchial epithelium did not show the observed changes in response to 2-MeOE 2 treatment ( Figure 5) .
To determine whether, wild-type p53 protein induction was responsible for 2-MeOE 2 mediated apoptosis, we treated our previously described H226b p53 antisense clones (AS) with 2-MeOE 2 (Mukhopadhyay et al, 1993) . The H226b (NSCLC) cell line (wt p53) was stably transfected with antisense p53 cDNA and individual G418 resistant clones expressing a reduced level of p53 protein were examined for their responses to 2-MeOE 2 mediated apoptosis. Two p53 antisense clones and their parental H226b cell lines were treated with 2-MeOE 2 for 48 h and apoptotic cells were analysed by FACScan after TdT and supravital dye (PI) staining. Apoptosis was Figure 4 Apoptotic H460 cells were detected by TUNEL assay as described earlier (Fujiwara et al., 1994) using biotinylated dUTP and 100 U/ml TdT enzyme in cacodylate buer. The avidin-biotin complex was detected using Vectastain Elite kit (Vector Lab, Burlingame, CA). (Figure 6 ). Although the p53 protein accumulated in the antisense clones after 2-MeOE 2 treatment, it was reduced twofold as compared to the control the H226b cell line as revealed by Western blotting (data not shown). These data further support the notion that the elevated level of wild-type p53 protein in the 2-MeOE 2 treated cell line was responsible for the resulting apoptosis.
The wild-type p53 protein is highly dynamic and undergoes conformational alterations depending on the proliferative state of the cell (Milner et al., 1990) . With the apparent conformational¯exibility of the wild-type p53 protein, pharmacologic intervention might be able to stabilize the protein in a functionally active state. It has previously been shown that Geldanamycin could selectively alter the conformation of mutated p53 and the biochemical properties of the protein (Blagosklonny et al., 1995). Wild-type p53 protein turnover in 2-MeOE 2 treated H460 cell line was compared with that of untreated control parental cell line (Figure 7) . Results indicated that the half-life of the wild-type p53 protein was increased to more than 16 h after 2-MeOE 2 treatment in H460 cell line. Thus, posttranslational modi®cations induced by 2-MeOE 2 may result in the higher p53 protein levels observed. p53 protein stabilization has also been reported during cmyc induced apoptosis in NIH3T3-LI mouse ®broblast (Hermeking et al., 1995) .
It appears that the lung tumor cell line undergoes apoptosis after 2-MeOE 2 treatment, which is related to the increased level of wild-type p53 expression. A mutation in the p53 gene often functionally inactivates the p53 gene and contributes to malignant progression (Vogelstein et al., 1992; Elledge et al., 1995) . Accumulation of wild-type p53 protein may cause the cell to enter one of two pathways: cell cycle arrest (Kuerbitz et al., 1992) or programmed cell death or apoptosis (Yonish-Rouach et al., 1991; Ryan et al., 1993) . The exact mechanism through which the wildtype p53 induces apoptosis is not clearly understood. Some studies have shown that p53 acts as a transcriptional activator in the induction of apoptosis (Yonish-Rouach et al., 1996) , while others suggested that p53 may induce apoptosis in the absence of transcriptional activation (Wagner et al., 1994) . Our results suggest that the high level of wild-type p53 protein resulting from the 2-MeOE 2 treatment may be responsible for induction of apoptosis. Our twodimensional electrophoretic analysis of whole cell proteins from control and 2-MeOE 2 treated H460 cells indicated that seven dierent isoforms of p53 underwent dierent level of phosphorylation with three being selectively expressed after 2-MeOE 2 treatment (Maxwell et al., 1996) . Thus, speci®c phosphorylation events generating these forms of p53 could lead to p53 protein stabilization and regulation of apoptosis. Another possibility is that increased stability of wtp53 could be due to 2-MeOE 2 induced endogneous eector molecules which may bind and modulate p53 conformation resulting in increased stability of the protein.
Interestingly, 2-MeOE 2 has no eect on p53 protein expression and apoptosis in human normal bronchial epithelial cells. These ®ndings suggest that the induction of wild-type p53 by 2-MeOE 2 treatment could be dependent on the cell type or`cellular context' in which it is activated. Alternatively, according to the previous report (Canver et al, 1994) estrogen receptors are selectively expressed in the lung cancer tissue and not in normal lung. 2-MeOE 2 being a metabolic byproduct of oestrogen, could be internalized by an estrogen receptor mediated pathway. This could provide an explanation why normal bronchial epithelial cells presumably containing wtp53 are not aected after 2-MeOE 2 treatment. These studies are in progress.
Studies on the eects of steroids on p53 function are limited. When estrogen dependent breast cancer cell lines were grown in charcoal treated fetal calf serum, the p53 level declined to 10% but supplementation with 1 nM estradiol restored p53 to its normal level (Hurd et al., 1995) . In a tumor model, estrogen dependent MCF-7 breast cancer cell line mitosis was induced following injection of the mice with estrogen with an Figure 6 H226b and its p53 antisense clones were examined for apoptosis following 48 h of 5 mM 2-MeOE 2 or 5 mM Epiestriol treatment. Apoptosis was measured by¯ow cytometry technique, using propidium iodide (PI) uptake in non-permiabilized cells as described (Zamai et al., 1996) . Percent apoptotic cell death was calculated. The experiment was repeated three times. C, Control untreated cell line, Mec, cells were treated with Epiestriol; Met, cells were treated with 2-MeOE 2 . H226b Con, parental cell line; H226#C5AS and H226b#6AS are individually selected stable p53 antisense clones as described previously (Mukhopadhyay et al., Stability of wt p53 protein in 2-MeOE 2 treated H460 cell line was examined. Cells were treated with 5 mM of 2-MeOE 2 for 24 h. Control mock treated and 2-MeOE 2 treated H460 cells were then incubated with 10 mg/ml cyclohexamide in drug free medium for dierent time intervals and total cell extracts were prepared. The total proteins were separated on 10% SDSpolyacrylamide gel and the p53 and actin proteins were detected by Western blot analysis using monoclonal antibodies as described earlier. (Thompson et al., 1990) . Another study showed that pretreatment with 17 b-estradiol protected MCF-7 cells from apoptosis by increasing the production of bcl-2, an anti-apoptotic protein (Wang et al., 1995) . 2-MeOE 2 is a natural byproduct of estrogen which is non-toxic to normal cells and has been shown to have no cytotoxic eect on normal human skin ®broblasts even at a 100 mM concentration (Fotsis et al., 1994) . It has been shown that some microtubule stabilizing and distabilizing agents can increase p53 levels in MCF-7 cells which are growth arrested at G 2 -M (Tishler et al., 1995) . 2-MeOE 2 has a microtubule disrupting activity and competes for the colchicine binding site, but this drug did not interfere with the distribution of lung tumor cells in the dierent phases of cell cycle. These data suggest that 2-MeOE 2 acts through a separate pathway for activating p53 and subsequent p53-dependent processes. Oral administration of 2-MeOE 2 in mice appears to be a potent inhibitor of capillary formation in solid tumors and reduces their growth (Fotsis et al., 1994) . p53 also induces the antiangiogenic molecule thrombospondin. The expression of thrombospondin may be regulated by the enhanced p53 level induced by 2-MeOE 2 . In conclusion, 2-MeOE 2 appears to be involved in pharmacologic restoration of p53 mediated apoptotic cell death in lung cancer cell lines. We have shown that in these lung cancer cell lines 2-MeOE 2 induces endogenous wild-type p53 protein post-transcriptionally with associated bypass of the G 1 -S checkpoint and apoptosis.
